| Riley Jane Hasenour, OTR | |
|
1956 S 1025 E # R, Birdseye, IN 47513-9419 | |
| (812) 639-0676 | |
| Not Available |
| Full Name | Riley Jane Hasenour |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 1956 S 1025 E # R, Birdseye, Indiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407450679 | NPI | - | NPPES |
| UNKNOWN | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Riley Jane Hasenour, OTR 1956 S 1025 E # R, Birdseye, IN 47513-9419 Ph: (812) 639-0676 | Riley Jane Hasenour, OTR 1956 S 1025 E # R, Birdseye, IN 47513-9419 Ph: (812) 639-0676 |
News Archive
Vibration therapy may be an effective nonpharmacologic intervention to increase bone mass in patients with thalassemia, US researchers report
ImmunoGen, Inc., a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentation of favorable clinical findings with SAR3419 (coltuximab ravtansine) from the STARLYTE Phase II trial in diffuse large B-cell lymphoma (DLBCL).
In a new publication that appears in Human Molecular Genetics, the laboratory of Christine DiDonato, PhD reports on their pharmacological characterization of the drug RG3039, demonstrating that it can extend survival and improve function in two spinal muscular atrophy (SMA) mouse models.
Very preterm infants are often sick and require antibiotic treatment to save their lives. However, when this form of therapy lasts for 20 months or more, it may affect the gut microbiome over the long-term in addition to its acute effects.
› Verified 9 days ago